A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Henan Provincial People'S Hospital
Zhengzhou, Henan, China
- Hubei Cancer Hospital
Wuhan, Hubei, China
- the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
- Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
- the First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, Shaanxi, China
- Shandong Cancer Hospital & Institute
Jinan, Shandong, China
- Sichuan Cancer Hospital
Chengdu, Sichuan, China
- Sichuan Provincial People'S Hospital
Chengdu, Sichuan, China
- Ningbo No.2 Hospital
Ningbo, Zhejiang, China
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2023
- Primary completion
- 31 Dec 2024
- Completion
- 30 Jun 2026
- Last update posted
- 22 Nov 2023
- Registered enrollment
- 99
- Registry id
- NCT06143735
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.